Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

PubMed  Google Scholar 

Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.

Article  CAS  PubMed  Google Scholar 

Mateo J, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019;75(2):285–93.

Article  PubMed  Google Scholar 

Helgstrand JT, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts. Cancer. 2018;124(14):2931–8.

Article  PubMed  Google Scholar 

Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

PubMed  Google Scholar 

Antonarakis ES, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2020;38(5):395–405.

Article  CAS  PubMed  Google Scholar 

Diamantis N, Banerji U. Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer. 2016;114(4):362–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sweat SD, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.

Article  CAS  PubMed  Google Scholar 

Kaittanis C, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215(1):159–75.

Article  CAS  PubMed  Google Scholar 

Sartor O, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehner K, et al. High-volume mCRPC is associated with decreased cancer specific survival in patients on second-generation hormone therapy in the post docetaxel setting. J Clin Oncol. 2023;41(6suppl):192–192.

Article  Google Scholar 

Ferriero M et al. Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort. Cancers (Basel), 2023. 15(19).

Kratochwil C, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536–44.

Article  PubMed  Google Scholar 

Zhao J, et al. Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. BJU Int. 2018;122(6):994–1002.

Article  PubMed  Google Scholar 

Ahmadzadehfar H, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8(61):103108–16.

Article  PubMed  PubMed Central  Google Scholar 

Sweeney CJ, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosar F, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49(5):1584–94.

Article  CAS  PubMed  Google Scholar 

Scher HI, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402–18.

Article  PubMed  PubMed Central  Google Scholar 

Hofman MS, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.

Article  CAS  PubMed  Google Scholar 

Hofman MS, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

Francini E, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018;78(12):889–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mader N, et al. Extended therapy with [(177)Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(6):1811–21.

Article  PubMed  PubMed Central  Google Scholar 

Buelens S et al. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol, 2018. 36(4): p. 158 e13-158 e20.

Al-Ibraheem A et al. From Despair to Hope: First Arabic Experience of (177)Lu-PSMA and (161)Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel), 2024. 16(11).

Pouliot F, et al. Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study. J Nucl Med. 2024;65(11):1710–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derlin T, et al. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. Prostate. 2023;83(11):1076–88.

Article  CAS  PubMed  Google Scholar 

Swiha M, et al. Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes. J Nucl Med. 2024;65(6):904–8.

Article  CAS  PubMed  Google Scholar 

Current K, et al. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity. Clin Cancer Res. 2020;26(12):2946–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gafita A, et al. Tumor Sink Effect in (68)Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2022;63(2):226–32.

Article  CAS  PubMed  Google Scholar 

Zamanian A et al. The tumor sink effect on PSMA-PET/CT in metastatic prostate cancer and its implications for PSMA-RLT: insight from the 3TMPO study. J Nucl Med, 2024. 65.

Rosar F, et al. Pilot experience of [(161)Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry. Theranostics. 2025;15(17):9019–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdlkadir AS, et al. Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review. Nucl Med Mol Imaging. 2025;59(1):50–61.

Article  PubMed  Google Scholar